Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
== Society and culture == In the late 2010s and early 2020s, a social media trend emerged promoting the use of methylene blue for various medical purposes, including anti-aging, metabolism enhancement, cognitive improvement, cancer treatment, and COVID-19 treatment. Currently there is no scientific consensus on, and no FDA approval for, its effectiveness and safety for these purposes. Medical experts cautioned that methylene blue can be toxic in high doses and may interact with other medications, potentially reducing their effectiveness or causing unforeseen side effects. Therefore, it should only be used under a doctor's prescription. This trend probably started following the publication of a few scientific papers exploring the potential of methylene blue for treating some medical conditions, such as progeria, and skin aging. It was also explored as part of anticancer photodynamic therapy using lasers. One systematic review of the studies expresses optimism but emphasizes the need for more extensive research to confirm methylene blue's clinical applications. Another review takes a more critical stance, stating that "it is obvious that the clinical use of [methylene blue] represents a rather controversial problem given the heterogeneity of available data and the lack of preclinical data, which is in conflict with standards of safe use of such substances in human medicinal practice". In January 2025, Robert F. Kennedy Jr, then the U.S. health secretary nominee, was filmed adding droplets of an unidentified blue liquid to his drink during a flight.
Human rights are guaranteed in the Federal Constitution. They fall under the Ministry of Human Rights established in August 2013. The central authorities concurrently inaugurated a National Human Rights Day, endorsed an official Human Rights Roadmap, and completed Somalia's first National Gender Policy. However, both male and female same-sex sexual activity are punishable by death within Somalia. On 3 October 2020, a UN human rights investigator raised concerns over Somali government's backtracking of human rights commitments.
== Effects of ingestion == Datura is considered a deliriant. Due to the potent combination of anticholinergic substances it contains, Datura intoxication typically produces the effects of anticholinergic delirium (usually involving a complete or relative inability to differentiate reality from fantasy); bizarre thoughts, hyperthermia; tachycardia; bizarre and possibly violent behavior; dry skin; dry mouth; illusions; and severe mydriasis (dilated pupils) with resultant painful photophobia that can last several days. Muscle stiffness, urinary retention, temporary paralysis, disrobing, emotional bluntness, dysphoria and confusion are often reported, and pronounced amnesia is another commonly reported effect. The psychoactive alkaloids scopolamine and atropine are also both known for their characteristic hyperactive effects and ability to cause stark and dream-like hallucinations. The onset of symptoms generally occurs around 30 to 60 minutes after ingesting the herb. These symptoms generally last from 24 to 48 hours, but have been reported in some cases to last two weeks or longer.
Hemodiafiltration is a combination between hemodialysis and hemofiltration, thus used to purify the blood from toxins when the kidney is not working normally and also used to treat acute kidney injury (AKI).
Sources: en.wikipedia.org
== Synthesis == L-Tellurocystine has been prepared in low yield from a protected form of 3-iodoalanine. Thus, methyl (2R)-2-[(tert-butoxycarbonyl)amino]-3-iodopropionate reacts with lithium telluride to produce tellurocystine.
For instance, in Mexico in 2009, "personal use" quantities were established for a number of drugs – cannabis (5 g), cocaine (0.5 g), heroin (50 mg), methamphetamine (40 mg), LSD (0.015 mg) – possession of which would result in a referral for treatment. A 2023 briefing to the European Parliament noted: "The UN bodies monitoring compliance with the conventions seem to have come to accept these policy choices" of tolerance or administrative rather than criminal penalties.
==== Possible prebiotic environments ==== The symmetry-breaking and chiral amplification of racemic RAO only requires a prebiotic environment where RAO is available and can interact with spin-polarized magnetic surfaces. One suggested environment is an evaporative lake with magnetic sediments, such as magnetite or greigite, which gain a statistically uniform net magnetization on a hemisphere scale from the Earth's geomagnetic field. These environments could have been widespread on the early Earth, and wet-drying cycling within and at the edges of these lakes could facilitate both crystallization and replenishment of RAO, along with other prebiotic precursors important for early life.
Later that year, tapentadol was approved in Europe. In 2011, Nucynta ER, an extended release formulation of tapentadol, was released in the United States for management of moderate to severe chronic pain and received Food and Drug Administration approval the following year for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. After annual sales of $166 million, in January 2015, Johnson & Johnson sold its rights to market tapentadol in the US to Depomed for $1 billion. The drug was manufactured at a plant located on the island of Puerto Rico that was hit by Hurricane Maria in 2017 causing a major shortage in the drug's availability. In January 2018 Depomed sold off the manufacturing of the drug and licensed it to Collegium Pharmaceutical for $10 million up front with an annual royalty payment of a minimum $135 million for the next 4 years. This combination of events has caused additional short supply of the drug leaving patients who depend on it to seek alternative treatments.
== Processing == Designing food for consumption in space is an often difficult process. Foods must meet a number of criteria to be considered fit for space. Food must be physiologically appropriate, in that it must be nutritious, easily digestible, and palatable. Secondly, the food must be engineered for consumption in a zero-gravity environment. As such, the food must be light, well packaged, fast to serve, and require minimal cleaning up. Finally, foods require a minimum of energy expenditure throughout their use; they must store well, open easily, and leave little waste behind (foods that tend to leave crumbs, for example, are ill-suited for space). Carbonated drinks have been tried in space but are not favored due to changes in belching caused by microgravity. Without gravity to separate the liquid and gas in the stomach, burping results in a kind of vomiting called "wet burping". Coca-Cola and Pepsi were first carried on STS-51-F in 1985. Coca-Cola has flown on subsequent missions in a specially designed dispenser that utilizes BioServe Space Technologies hardware used for biochemical experiments. Space Station Mir carried cans of Pepsi in 1996.
Sources: en.wikipedia.org
The mtFAS pathway takes place in the mitochondrial matrix and consists of at least six separate enzymes, each encoded by its own gene. This sets it apart from cytosolic fatty acid synthesis, where the multifunctional enzyme fatty acid synthase (FASN) contains all enzymatic activities within a single polypeptide chain and is encoded by a single gene. Despite this structural difference, mtFAS and cytosolic fatty acid synthesis use the same chemistry to build fatty acids. The mitochondrial acyl carrier protein (mtACP) serves as a scaffold for fatty acyl chains but requires prior phosphopantetheinylation by AASDHPPT to convert it from the inactive apo to the active holo form. This activation represents the first step of mtFAS and introduces a 4'-phosphopantetheine group, which provides the thiol group to which the fatty acyl chain is covalently attached and subsequently elongated, while also functioning as a flexible swinging arm. This allows the fatty acyl chain to swing out of its hydrophobic pocket within mtACP and enter those of interacting proteins. Malonyl-CoA provides the substrate for mtFAS and is generated in mitochondria from acetyl-CoA by mtACC1 (a mitochondrial isoform of acetyl-CoA carboxylase 1) and from malonate by acyl-CoA synthetase family member 3 (ACSF3). However, the precise mitochondrial source of malonyl-CoA remains under debate. The malonyl group is transferred from malonyl-CoA to mtACP by malonyl-CoA:ACP transacylase (MCAT), forming malonyl-mtACP.
On 26 October 1985, the government extended the emergency to the western Cape, where it said that the situation had reached a "state of pre-insurrection"; confrontations there had heightened since August, when the state had suppressed a planned march on Pollsmoor Prison, where Nelson Mandela was being held. In all, the emergency degree was applied to detain between 8,000 and 12,000 people without trial.
=== 1980s === 1982: Nephrologist Leah Lowenstein became the first woman dean of a co-educational medical school in the United States. 1983: Barbara McClintock received the Nobel Prize in Physiology or Medicine for her discovery of genetic transposition; she was the first woman to receive that prize without sharing it, and the first American woman to receive any unshared Nobel Prize. 1984: Kathryn D. Sullivan becomes the first American woman to walk in space. 1988: Patricia Bath was the first African American woman to receive a medical patent, which was her invention of laser cataract treatment. 1988: Gertrude B. Elion received the Nobel Prize in Physiology or Medicine along with James W. Black and George H. Hitchings "for their discoveries of important principles for drug treatment".
=== Victims === On 17 September 2008, Health Minister Chen Zhu stated tainted milk formula had "sickened more than 6,200 children, and that more than 1,300 others, mostly newborns, remain hospitalized with 158 suffering from acute kidney failure". By 23 September, about 54,000 children were reported to be sick and four had died. An additional 10,000 cases were reported from the provinces by 27 September. A World Health Organization official said 82% of the children made ill were 2 years of age or below. The Hong Kong Centre for Food Safety said that 99 per cent of the victims were aged under 3 years. Ten Hong Kong children were diagnosed with kidney problems, at least four cases were detected in Macau, and six in Taiwan. Non-human casualties included a lion cub and two baby orangutans which had been fed Sanlu infant formula at Hangzhou Zoo. The government said on 8 October it would no longer issue updated figures "because it is not an infectious disease, so it's not absolutely necessary for us to announce it to the public". Reuters compiled figures reported by local media across the country, and said the toll stood at nearly 94,000 at the end of September, excluding municipalities. Notably, 13,459 children had been affected in Gansu, Reuters quoted Xinhua saying Henan had reported over 30,000 cases, and Hebei also had nearly 16,000 cases. In late October, the government announced health officials had surveyed 300,000 Beijing families with children less than 3 years old.
==== Fibrates ==== Fibrates, known as derivatives of fibric acids, are peroxisome proliferator-activated receptor alpha (PPAR-α) agonists primarily used for lowering TG levels and management of atherogenic dyslipidemia. Typical drugs of the class include fenofibrate, bezafibrate, ciprofibrate and gemfibrozil. Through activation of PPAR-α receptors, fibrates decreases circulating TG via upregulation of lipoprotein lipase (LPL) expression and downregulation of apolipoprotein C-III (ApoC-III) gene expression. LPL is a hepatic enzyme involved in lipolysis, whereas ApoC-III is an inhibitor of LPL. Comparable to statins and ezetimibe, fibrates are usually well-tolerated with mild adverse reactions, with the exception of gemfibrozil. Some of the more prevalent side effects are minor gastrointestinal disturbances such as abdominal pain and cholithiasis on account of the increased excretion of biliary cholesterol. Among atypical adverse effects, myositis can occur in patients under gemfibrozil therapy, especially in those with renal insufficiency or under co-treatment with statins. In contrast, the risk of myopathy is much lower if fenofibrate is used in replacement of gemfibrozil owing to its different pharmacokinetic pathway. Other rare effects are increased serum transaminase levels, agranulocytosis and anaemia. As fenofibrate possess the same binding mechanism as warfarin in the blood, this combination should be addressed with caution as fenofibrate may potentiate the anticoagulant effect of warfarin.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.